Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M000966200 on April 3, 2000

J. Biol. Chem., Vol. 275, Issue 23, 17358-17363, June 9, 2000
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/23/17358    most recent
M000966200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montgomery, R. B.
Right arrow Articles by Stahl, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montgomery, R. B.
Right arrow Articles by Stahl, W. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters beta -Tubulin Isotype Expression*

R. Bruce MontgomeryDagger §, Junitta GuzmanDagger , Donald M. O'Rourke, and William L. Stahl||

From the Departments of Dagger  Medicine and Oncology and || Physiology, Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington 98108 and the  Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Oncogenic transformation confers resistance to chemotherapy through a variety of mechanisms, including suppression of apoptosis, increased drug metabolism, and modification of target proteins. Oncogenic epidermal growth factor receptor family members, including EGFRvIII and HER2, are expressed in a broad spectrum of human malignancies. Cell lines transfected with EGFRvIII and HER2 are more resistant to paclitaxel-mediated cytotoxicity, and tubulin polymerization induced by paclitaxel is suppressed compared with cells expressing wild type epidermal growth factor receptor. Because differential expression of beta -tubulin isotypes has been proposed to modulate paclitaxel resistance, we analyzed beta -tubulin isotypes expressed in cell lines transfected with different oncogenes. EGFRvIII- and HER2-expressing cells demonstrated equivalent total beta -tubulin protein compared with cells transfected with wild type receptor or untransfected controls. EGFRvIII-expressing cells demonstrated increases in class IVa (2.5-fold) and IVb (3.1-fold) mRNA, and HER2-expressing cells showed increases in class IVa (2.95-fold) mRNA. Expression of oncogenic Ha-Ras did not change class IV RNA levels significantly. Inhibition of EGFRvIII kinase activity using a mutant allele with an inactivating mutation in the kinase domain decreased expression of class IVa by 50% and partially reversed resistance to paclitaxel. Expression of oncogenic epidermal growth factor receptor family members is associated with modulation of both beta -tubulin isotype expression and paclitaxel resistance in cells transformed by expression of the receptor. This effect on tubulin expression may modulate drug resistance in human malignancies that express these oncogenes.

* This work was supported by Veterans Affairs Merit Review and National Institutes of Health Grant CA60782 (to R. B. M. and W. L. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom reprint requests should be addressed: Oncology Division, Veteran Affairs Puget Sound HCS (111ONC), 1660 S. Columbian Way, Seattle, WA 98108. Tel.: 206-764-2709; Fax: 206-764-2851; E-mail: rbmontgo@u.washington.edu.

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
P. Chaudhry and E. Asselin
Resistance to chemotherapy and hormone therapy in endometrial cancer
Endocr. Relat. Cancer, June 1, 2009; 16(2): 363 - 380.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
Ann. Onc., February 1, 2008; 19(2): 223 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al.
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Kollmannsberger, M. Schittenhelm, F. Honecker, J. Tillner, D. Weber, K. Oechsle, L. Kanz, and C. Bokemeyer
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Ann. Onc., June 1, 2006; 17(6): 1007 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Arai, Y. Matsumoto, Y. Nagashima, and K. Yagasaki
Regulation of Class II {beta}-Tubulin Expression by Tumor Suppressor p53 Protein in Mouse Melanoma Cells in Response to Vinca Alkaloid
Mol. Cancer Res., April 1, 2006; 4(4): 247 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Fishman, C. R. Garrett, G. R. Simon, A. A. Chiappori, R. M. Lush, W. R. Dinwoodie, J. J. Mahany, A. M. Dellaportas, A. Cantor, A. Gollerki, et al.
Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies
Clin. Cancer Res., January 15, 2006; 12(2): 523 - 528.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
H. Takenouchi, N. Kiyokawa, T. Taguchi, J. Matsui, Y. U. Katagiri, H. Okita, K. Okuda, and J. Fujimoto
Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells
J. Cell Sci., August 1, 2004; 117(17): 3911 - 3922.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
C. D. Katsetos, A. Legido, E. Perentes, and S. J. Mork
Class III {beta}-Tubulin Isotype: A Key Cytoskeletal Protein at the Crossroads of Developmental Neurobiology and Tumor Neuropathology
J Child Neurol, December 1, 2003; 18(12): 851 - 866.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. McDaid, S. Mani, H.-J. Shen, F. Muggia, D. Sonnichsen, and S. B. Horwitz
Validation of the Pharmacodynamics of BMS-247550, an Analogue of Epothilone B, during a Phase I Clinical Study
Clin. Cancer Res., July 1, 2002; 8(7): 2035 - 2043.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman
Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer
J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Toppmeyer, A. D. Seidman, M. Pollak, C. Russell, K. Tkaczuk, S. Verma, B. Overmoyer, V. Garg, E. Ette, M. W. Harding, et al.
Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel
Clin. Cancer Res., March 1, 2002; 8(3): 670 - 678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Chatterjee, H. A. Pulido, S. Koul, N. Beleño, A. Perilla, H. Posso, M. Manusukhani, and V. V. V. S. Murty
Mapping the Sites of Putative Tumor Suppressor Genes at 6p25 and 6p21.3 in Cervical Carcinoma: Occurrence of Allelic Deletions in Precancerous Lesions
Cancer Res., March 1, 2001; 61(5): 2119 - 2123.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement